Trump to impose 100% tariff on China starting November 1
Investing.com -- Hoth Therapeutics Inc (NASDAQ:HOTH) stock rose 9.8% in premarket trading Wednesday after the clinical-stage biopharmaceutical company announced an expansion of its artificial intelligence initiative through a new NVIDIA AI Enterprise subscription license.
The company secured annual NVIDIA AI Enterprise Essentials licenses to support its GPU-powered infrastructure, enabling advanced machine learning and neural network modeling capabilities for pharmaceutical research. This technology will be used to accelerate data-driven drug development, preclinical modeling, and predictive analytics.
According to Robb Knie, CEO of Hoth Therapeutics , "Our continued investment in NVIDIA’s AI platform reflects our long-term commitment to integrating next-generation technology across our R&D programs." He added that the company is "harnessing NVIDIA’s enterprise-grade AI infrastructure to accelerate the development of therapies like HT-001, HT-KIT, and our oncology programs."
The NVIDIA AI Enterprise environment will allow Hoth’s scientific and data teams to deploy predictive pharmacology and toxicity models, integrate multi-omic and patient-derived data, support clinical trial simulation, and leverage secure GPU-accelerated cloud infrastructure.
Hoth Therapeutics focuses on developing innovative therapies for dermatological and oncological disorders. The company’s AI initiative is part of its broader strategy of digital transformation in biotechnology, aimed at optimizing development timelines, reducing costs, and improving therapeutic outcomes.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.